The promise of the Precision Medicine Initiative is a specific treatment for a specific disease. A logical extension of that thinking is that perhaps we should be viewing every disease as a rare disease. That was the focus of a HUBWeek panel hosted by STAT.
STAT’s national biotech reporter, Damian Garde, led the panel. He was joined by Dr. Anna Greka, a researcher at the Broad Institute; Michael Ringel, a senior partner and managing director at the Boston Consulting Group; Dr. Matthew Meyerson, director of the Center for Cancer Genome Discovery at the Dana-Farber Cancer Institute; and Dr. David Grayzel, a partner at Atlas Venture, which invests in novel therapeutics, often those near a first human clinical test. Here are excerpts of their discussion, edited for length and clarity.
